G-Cimp Status Prediction Of Glioblastoma Samples Using mRNA Expression Data

Glioblastoma Multiforme (GBM) is a tumor with high mortality and no known cure. The dramatic molecular and clinical heterogeneity seen in this tumor has led to attempts to define genetically similar subgroups of GBM with the hope of developing tumor specific therapies targeted to the unique biology within each of these subgroups. Recently, a subset of relatively favorable prognosis GBMs has been identified. These glioma CpG island methylator phenotype, or G-CIMP tumors, have distinct genomic copy number aberrations, DNA methylation patterns, and (mRNA) expression profiles compared to other GBMs. While the standard method for identifying G-CIMP tumors is based on genome-wide DNA methylation data, such data is often not available compared to the more widely available gene expression data. In this study, we have developed and evaluated a method to predict the G-CIMP status of GBM samples based solely on gene expression data.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  R. Peng.  Reproducible Research in Computational Science , 2011, Science.

[3]  Tieliu Shi,et al.  A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data , 2010, The Pharmacogenomics Journal.

[4]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[5]  K. Gunderson,et al.  High density DNA methylation array with single CpG site resolution. , 2011, Genomics.

[6]  M. Esteller,et al.  Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome , 2011, Epigenetics.

[7]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[8]  Subha Madhavan,et al.  Rembrandt: Helping Personalized Medicine Become a Reality through Integrative Translational Research , 2009, Molecular Cancer Research.

[9]  John P A Ioannidis,et al.  Improving Validation Practices in “Omics” Research , 2011, Science.

[10]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[11]  Yuri Kotliarov,et al.  Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. , 2009, Cancer research.

[12]  John Quackenbush,et al.  Why Is There a Lack of Consensus on Molecular Subgroups of Glioblastoma? Understanding the Nature of Biological and Statistical Variability in Glioblastoma Expression Data , 2011, PloS one.

[13]  C. Brennan,et al.  Molecular subclassification of diffuse gliomas: Seeing order in the chaos , 2011, Glia.

[14]  M. Wolter,et al.  Unraveling the Glioma Epigenome—From Molecular Mechanisms to Novel Biomarkers and Therapeutic Targets , 2011, Brain pathology.

[15]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[16]  K. Kangawa,et al.  High plasma concentrations of human atrial natriuretic polypeptide in aged men. , 1987, The Journal of clinical endocrinology and metabolism.

[17]  C. Sotiriou,et al.  Evaluation of the Infinium Methylation 450K technology. , 2011, Epigenomics.

[18]  P. Meltzer,et al.  DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. , 2012, The Journal of clinical endocrinology and metabolism.